Information Provided By:
Fly News Breaks for March 8, 2019
Mar 8, 2019 | 07:05 EDT
H.C. Wainwright analyst Swayampakula Ramakanth lowered his price target for Idera Pharmaceuticals to $14 following this week's Q4 results and corporate update. The new target reflects additional dilution from the stock purchase agreement. The analyst keeps a Buy rating on the shares.
News For IDRA From the Last 2 Days
There are no results for your query IDRA